| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Ocular Therapeutix, Inc.'s insiders have reduced their positions by a net 63,819 shares worth roughly $568K. In the past 30 days, 0 insiders bought and 3 sold. The bias lately has been to the sell side.
Not all activity pointed one way: 3 insiders sold in the same window, though all of them still hold shares. Classified under Biotechnology (Health Care sector), OCUL's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 416.0K | - | - | |
| COO | 366.5K | $3.75M | - | |
| Other | 326.9K | $3.52M | - | |
| Other | 307.5K | $2.17M | -10,869 | |
| Other | 300.1K | $2.48M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | Kaiser Peter | Chief Development Officer | Sell | 2,967 | $8.20 | $24,329.40 | -1.1% | - | - | |
| May 26, 2026 | Heier Jeffrey S.61 | Chief Scientific Officer | Sell | 3,018 | $8.20 | $24,747.60 | -0.9% | - | - | |
| May 26, 2026 | Dugel Pravin | See Remarks | Sell | 21,156 | $8.20 | $173,479.20 | -0.8% | - | - | |
| Feb 23, 2026 | Heier Jeffrey S.61 | Chief Scientific Officer | Sell | 3,057 | $8.28 | $25,311.96 | -0.9% | -2.3% | - | |
| Feb 23, 2026 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,759 | $8.28 | $14,564.52 | -0.5% | -2.3% | - | |
| Feb 23, 2026 | Dugel Pravin | See Remarks | Sell | 20,056 | $8.28 | $166,063.68 | -0.7% | -2.3% | - | |
| Feb 23, 2026 | Kaiser Peter | Chief Development Officer | Sell | 2,810 | $8.28 | $23,266.80 | -1.0% | -2.3% | - | |
| Feb 20, 2026 | Waheed Nadia | Chief Medical Officer | Sell | 3,510 | $7.74 | $27,167.40 | -1.1% | - | - | |
| Feb 20, 2026 | Lindstrom Richard L Md65 | Director | Buy | 60,229 | $7.66 | $461,354.14 | +32.3% | - | - | |
| Feb 12, 2026 | Nayak Sanjay | Chief Strategy Officer | Sell | 10,348 | $9.04 | $93,545.92 | -3.0% | - | - |